Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cost Could Drag On Lilly's Baricitinib Outlook Despite Deepening Data

This article was originally published in Scrip

Executive Summary

Eli Lilly & Co. and partner Incyte Corp. have added to the growing dataset for their once-daily oral JAK1/JAK2 inhibitor baricitinib ahead of their planned filing by year-end, with detailed results from the pivotal Phase III RA-BEAM which showed the investigational therapy had superior patient-reported outcomes compared with AbbVie's market-leading injectable anti-TNF antibody, Humira (adalimumab), along with better response claims and structural improvements for patients.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts